2022
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapyPD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
Shu F, Punekar S, Velcheti V, Sanmamed M, Wang J. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy. Clinical Cancer Research 2022, 28: 3182-3184. PMID: 35648093, DOI: 10.1158/1078-0432.ccr-22-0541.Peer-Reviewed Original Research
2020
Chapter 4 Cancer Treatment-Related Thrombocytopenia
Punekar S. Chapter 4 Cancer Treatment-Related Thrombocytopenia. 2020, 17-20. DOI: 10.1016/b978-0-323-67241-2.00004-5.Peer-Reviewed Original Research